World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
30015
World Ranking
14499
National Ranking
7334

Neil H. Bander publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Neil H. Bander sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 326 publications — 22nd percentile

22% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Neil H. Bander D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Neil H. Bander sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Neil H. Bander is affiliated with Cornell University in the United States and has contributed extensively to medical research, particularly in the field of prostate cancer treatment and imaging. Their work intersects several areas within medicine, including radiology, nuclear medicine, oncology, and pulmonary and respiratory medicine.

The range of their research topics includes:

  • Prostate Cancer Treatment and Research
  • Radiopharmaceutical Chemistry and Applications
  • Medical Imaging Techniques and Applications
  • Mass Spectrometry Techniques and Applications
  • Cancer Immunotherapy and Biomarkers
  • Prostate Cancer Diagnosis and Treatment
  • Peptidase Inhibition and Analysis

Neil H. Bander has published articles in several scientific venues, frequently contributing to:

  • Journal of Clinical Oncology
  • The Prostate
  • Annals of Oncology
  • Cancer Research
  • The Journal of Urology

Some of their recent research papers include:

  • "Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer" (2023) published in JCI Insight
  • "Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591" (2023) published in Journal of Clinical Oncology
  • "A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals" (2021) published in European Journal of Nuclear Medicine and Molecular Imaging
  • "Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer" (2020) published in Urologic Oncology Seminars and Original Investigations
  • "Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer" (2021) published in Frontiers in Oncology

Frequent co-authors who have collaborated with Neil H. Bander include:

  • Scott T. Tagawa
  • Joseph R. Osborne
  • David M. Nanus
  • Ana M. Molina
  • Cora N. Sternberg

The main fields of study that encompass Neil H. Bander's research are:

  • Medicine

Their subfields of interest include:

  • Radiology, Nuclear Medicine and Imaging
  • Pulmonary and Respiratory Medicine
  • Oncology
  • Spectroscopy
  • Cancer Research

Best Publications

  • Renal-cell carcinoma.

    Robert J. Motzer;Neil H. Bander;David M. Nanus

  • Mutations of the VHL tumour suppressor gene in renal carcinoma

    J.R. Gnarra;K. Tory;Y. Weng;L. Schmidt

  • Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

    Jeffrey Hrkach;Daniel Von Hoff;Mir Mukkaram Ali;Elizaveta Andrianova

  • Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature

    Sam S. Chang;Victor E. Reuter;W. D. W. Heston;Neil H. Bander

  • Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

    Cora N. Sternberg;Alan Yagoda;Howard I. Scher;Robin C. Watson

  • Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen Also React with Tumor Vascular Endothelium

    He Liu;Peggy Moy;Sae Kim;Yan Xia

  • Tumor Therapy with Targeted Atomic Nanogenerators

    Michael R. McDevitt;Dangshe Ma;Lawrence T. Lai;Jim Simon

  • The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer

    Dimple Chakravarty;Andrea Sboner;Sujit S. Nair;Eugenia Giannopoulou

  • Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

    Neil H. Bander;Matthew Ivan Milowsky;David M. Nanus;Lale Kostakoglu

  • M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

    Cora N. Sternberg;Cora N. Sternberg;Alan Yagoda;Alan Yagoda;Howard I. Scher;Howard I. Scher;Robin C. Watson;Robin C. Watson

  • Constitutive and antibody-induced internalization of prostate-specific membrane antigen

    He Liu;Ayyoppan K. Rajasekaran;Peggy Moy;Yan Xia

  • Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy

    M Mangin;A C Webb;B E Dreyer;J T Posillico

  • Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.

    Jason P. Gleghorn;Erica D. Pratt;Denise Denning;He Liu

  • Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

    Medha S Darshan;Matthew S Loftus;Maria Thadani-Mulero;Ben P Levy

  • Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer

    Scott T. Tagawa;Matthew I. Milowsky;Michael Morris;Shankar Vallabhajosula

  • 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo

    Jason P. Holland;Vadim Divilov;Neil H. Bander;Peter M. Smith-Jones

  • Cancer Patient T Cells Genetically Targeted to Prostate-Specific Membrane Antigen Specifically Lyse Prostate Cancer Cells and Release Cytokines in Response to Prostate-Specific Membrane Antigen

    Michael C. Gong;Jean Baptiste Latouche;Anja Krause;Warren D W Heston

  • Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy

    Andrew Z. Wang;Andrew Z. Wang;Vaishali Bagalkot;Christophoros C. Vasilliou;Frank Gu

  • Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy.

    Anil K. Patri;Andrzej Myc;James Beals;Thommey P. Thomas

  • Phase I Trial of Yttrium-90--Labeled Anti--Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer

    Matthew I. Milowsky;David M. Nanus;Lale Kostakoglu;Shankar Vallabhajosula

Frequent Co-Authors

David M. Nanus
David M. Nanus Cornell University
Stanley J. Goldsmith
Stanley J. Goldsmith Cornell University
Paul J. Christos
Paul J. Christos Cornell University
Himisha Beltran
Himisha Beltran Harvard University
Steven M. Larson
Steven M. Larson Memorial Sloan Kettering Cancer Center
Michael J. Morris
Michael J. Morris Memorial Sloan Kettering Cancer Center
Jason S. Lewis
Jason S. Lewis Memorial Sloan Kettering Cancer Center
Warren D.W. Heston
Warren D.W. Heston Case Western Reserve University
Cora N. Sternberg
Cora N. Sternberg Cornell University
John W. Babich
John W. Babich Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring career pathways related to medicine provides students with additional flexibility and specialization opportunities. Many aspiring medical professionals may consider a support or leadership role in healthcare, and pursuing an online healthcare administration degree can open doors to hospital and clinic management positions. These programs offer foundational knowledge in business, policy, and healthcare systems.

For those looking to advance into higher leadership roles or specialized administration, enrolling in one of the cheapest online mha programs is a popular pathway. Completing a master’s degree in healthcare administration helps professionals qualify for executive positions and drive organizational change.

If your interests are in clinical practice, consider the cheapest bsn to dnp programs, which allow registered nurses to achieve a high level of clinical expertise and leadership in advanced nursing practice. Alternatively, future pharmacists can benefit from pursuing accredited online pharmacist programs to gain advanced clinical skills and qualify for licensure.

Whether your goal is in leadership, nursing, or pharmacy, these online degree options support a variety of rewarding career paths in the healthcare sector.

Best Scientists Citing Neil H. Bander

Trending Scientists

Recently Published Articles